Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Asset Writedowns and Impairment (2020 - 2025)

Journey Medical (DERM) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with $76000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Asset Writedowns and Impairment fell 88.67% year-over-year to $76000.0, compared with a TTM value of -$477000.0 through Sep 2025, down 162.27%, and an annual FY2024 reading of $516000.0, up 18.62% over the prior year.
  • Asset Writedowns and Impairment was $76000.0 for Q3 2025 at Journey Medical, up from -$441000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $3.0 million in Q2 2023 and bottomed at -$2.7 million in Q3 2023.
  • Average Asset Writedowns and Impairment over 5 years is $58578.9, with a median of $55000.0 recorded in 2022.
  • Peak annual rise in Asset Writedowns and Impairment hit 9632.26% in 2023, while the deepest fall reached 4920.0% in 2023.
  • Year by year, Asset Writedowns and Impairment stood at $115000.0 in 2021, then skyrocketed by 138.26% to $274000.0 in 2022, then plummeted by 120.8% to -$57000.0 in 2023, then plummeted by 438.6% to -$307000.0 in 2024, then soared by 124.76% to $76000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for DERM at $76000.0 in Q3 2025, -$441000.0 in Q2 2025, and $195000.0 in Q1 2025.